Genome-wide copy number analysis of cerebrospinal fluid tumor cells and their corresponding archival primary tumors  by Magbanua, Mark Jesus M. et al.
Genomics Data 2 (2014) 60–62
Contents lists available at ScienceDirect
Genomics Data
j ou rna l homepage: ht tp : / /www. journa ls .e lsev ie r .com/genomics-data /Data in BriefGenome-wide copy number analysis of cerebrospinal ﬂuid tumor cells
and their corresponding archival primary tumorsMark Jesus M. Magbanua a,b, Ritu Roy b,c, Eduardo V. Sosa a,b, Louai Hauranieh a,b, Andrea Kablanian a,b,
Lauren E. Eisenbud a,b, Artem Ryazantsev a,b, Alfred Au a,b, Janet H. Scott a,b,
Michelle Melisko a,b,1, John W. Park a,b,⁎,1
a Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA
b Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA
c Helen Diller Family Comprehensive Cancer Center Computational Biology Core, University of California San Francisco, San Francisco, California, USA⁎ Corresponding author at: 1600 Divisadero St. San Fr
Tel.: +1 415 502 3844; fax: +1 415 353 9592.
E-mail address: jpark@cc.ucsf.edu (J.W. Park).
1 These authors contributed equally to this manuscript.
http://dx.doi.org/10.1016/j.gdata.2014.04.003
2213-5960/© 2014 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 25 March 2014
Accepted 2 April 2014
Available online 18 April 2014A debilitating complication of breast cancer is the metastatic spread of tumor cells to the leptomeninges or cere-
brospinal ﬂuid (CSF). Patients diagnosed with this aggressive clinical syndrome, known as leptomeningeal carci-
nomatosis, have very poor prognosis. Despite improvements in detecting cerebrospinal ﬂuid tumor cells
(CSFTCs), information regarding their molecular biology is extremely limited. In our recent work, we utilized a
protocol previously used for circulating tumor cell isolation to purify tumor cells from the CSF. We then per-
formed genomic characterization of CSFTCs as well as archival tumors from the same patient. Here, we describe
the microarray data and quality controls associated with our study published in the Cancer Research journal in
2013 [1]. We also provide an R script containing code for quality control of microarray data and assessment of
copy number calls. The microarray data has been deposited into Gene Expression Omnibus under accession #
GSE46068.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).SpeciﬁcationsOrganism/cell
line/tissueTumor cells isolated from the cerebrospinal ﬂuid of breast cancer
patients diagnosed with leptomeningeal carcinomatosisSex Female
Sequencer or
array type2.4 K Bacterial Artiﬁcial Chromosome (BAC) ArrayData format Raw data: Sproc; normalized data: TXT
Experimental
featuresArray comparative genomic hybridization analysis was
performed on ampliﬁed tumorDNA versus normalmale genomic
referenceConsent All patients gave written informed consent under a protocol
approved by the UCSF Institutional Review BoardSample source
locationUniversity of California San FranciscoDirect link to deposited data
Deposited data can be found here http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE46068.ancisco, California 94115, USA.
. This is an open access article underExperimental design, materials and methods
Patient and clinical information
Fifteen (15) metastatic breast cancer patients who were diagnosed
with leptomeningeal carcinomatosis by standard cytology or by imag-
ing were enrolled in this study. Clinical information was obtained
from the patients' medical records. A majority of the patients were es-
trogen receptor (ER) positive (73%). Almost half were HER2 positive
(47%) while two cases were triple-negative (13%). Additionally, two-
thirds had concurrent brain metastasis (67%).
Isolation of CSFTCs
Approximately 4 to 10 mL of CSF samples were obtained via lumbar
puncture or via an Ommaya reservoir. Tumor cells were isolated from
the CSF samples via a two-step process involving immunomagnetic en-
richment followed by ﬂuorescence-activated cell sorting or IE/FACS [2].
Brieﬂy, samples were ﬁrst enriched for tumor cells using a magnetic
capture method involving iron particles coated with monoclonal anti-
bodies to the epithelial cell adhesion marker or EPCAM. Tumor cells
were further puriﬁed using FACS analysis. During cell sorting, events
that were positive for nuclear and EPCAM stains but were negative for
CD45 (leukocyte-speciﬁc marker) were considered CSFTCs.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1.Quality control of microarray data. Themedian absolute deviation (MAD) estimates
were used as ameasure of array data quality. The plot shows the frequency distribution of
MAD estimates for microarray data generated from 30 cerebrospinal ﬂuid tumor cell
(CSFTC)-samples collected from 13 metastatic breast cancer patients diagnosed with
leptomeningeal carcinomatosis. All the samples were considered evaluable since the
MAD estimates were b0.25, which is the threshold chosen for good quality array data.
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In a subset of patients (6 of 15), archival formalin-ﬁxed parafﬁn em-
bedded (FFPE) primary tumors, and in some cases loco-regional or dis-
tant metastasis including circulating tumor cells from blood, were
available and processed, as previously described [3]. Brieﬂy, whole cell
lysates were prepared from microdissected areas containing 70% tu-
mors. DNA from lysateswas processed in parallel withmatched CSFTCs,
as outlined in the next section.
Whole genome ampliﬁcation and array comparative genomic hybridization
Array comparative genomic hybridization (ACGH) analysis usually
requires DNA input that is roughly equivalent to genomic material
from several thousands of cells. Since CSFTCs are rare, we can only iso-
late small pools of CSFTCs. The few hundred picograms of genomic ma-
terial from these few cells require whole genome ampliﬁcation (WGA)
prior to downstreammolecular analysis. To reduce the likelihood of de-
tecting false positives (due to ampliﬁcation bias) when comparing
CSFTCs versus matched archival tumors, we subjected both sets of tu-
mors to the same WGA method [4]. Samples from 2 of the 15 patients
failed WGA product quality testing [4] and were excluded from further
analysis.
Ampliﬁed tumor DNA samples were then subjected to ACGH analy-
sis using a bacterial artiﬁcial chromosome (BAC) array containing 2464
clones printed in triplicate [5]. The BAC arrays were printed at the UCSF
Helen Diller Family Comprehensive Cancer Center Array Core. The
ACGH experimental protocol has been previously described in detail
[4]. Brieﬂy, the tumor (test sample) and reference DNA samples were
differentially labeled with Cy3 and Cy5 dyes, respectively, and co-
hybridized to a BAC array. A sex-mismatched (i.e., female vs. male) hy-
bridizationwas used as an internal control to detect a copy number gain
in X- and loss of Y-chromosomes in the female test sample. Post-
hybridization imaging data and analysis of the BAC array were done as
previously described [6]. The intensity values were used to calculate
Cy3/Cy5 ratios using the UCSF Spot Program. An in-house R package
‘Spot Correction’ was also used to remove systematic variations of un-
known origin across the array [7], including a correction that is based
on the GC content of the BAC clones [4].
Microarray data processing
The aCGH data was processed using the custom program SPROC [8]
in order to automatically ﬁlter out data points with low DAPI intensity,
low correlation between Cy3 and Cy5 within each spot, and low refer-
ence/DAPI signal intensity. Clones whose ratios that were derived
from only one of the triplicate spots or with a triplicate log2 SD N 0.2
were set as “missing”. The clones were mapped to the May 2004 freeze
of the human DNA sequence.
Quality control of aCGH data
The median absolute deviation (MAD) estimates (see below) were
used as a measure of the quality of the microarray data. Array data
with aMAD estimate b0.25was considered “good quality”. A histogram
of MAD estimates showed that all samples passed the MAD threshold
(Fig. 1). Visual inspection of each aCGH proﬁle was also performed to
conﬁrm results. Themicroarray and sample annotation data for 30 sam-
ples from 13 patients were deposited in Gene expression Omnibus
under accession number GSE46068.
MAD and copy number calls
The microarray data was subjected to circular binary segmenta-
tion (CBS) [9] as implemented in the DNAcopy package from
Bioconductor [10]. The algorithm translates intensity measurementsinto regions of equal copy number to make gain/loss/ampliﬁcation
calls (see Supplementary Information for R code). The median abso-
lute deviation (MAD), scaled by the factor 1.4826, of the difference
between the observed and segmented values of the autosomal clones
was used to estimate sample-speciﬁc experimental variation. For
copy number calls in each sample, a segment was declared to be
gained or lost if the average log2 ratio was at least twice the sample
MAD away from the median segmented value of the autosomal
clones.
Basic analysis
Genomic alterations
To quantitate the extent of the genomic instability in each sample,
we calculated the fraction of genome altered (FGA; i.e., the fraction of
genome lost and gained), as previously described [11]. Brieﬂy, the FGA
was calculated by assigning each clone a distance equal to the sum of
one half of the distance between its own center and that of its neighbor-
ing clones or to the end of the chromosome for the cloneswith only one
neighbor.
Next, we compared the FGA between CSFTCs and matched primary
tumors from patients 4011, 4015, 4037, 4038, 4039, and CSF6. Interest-
ingly, the FGA in CSFTCs was signiﬁcantly higher as compared to that of
the matched primary tumors (lost: 11% vs. 4%; gained: 12% vs. 10% re-
spectively) (p = 0.0277 sign test) [1] (Fig. 2).
Copy number analysis using Nexus
We also analyzed the CSFTC ACGHmicroarray data from 13 patients
usingNexus 6.1 software (Biodiscovery) [3]. To determine chromosome
gains and losses, we chose 0.20 and −0.20, and 0.6 and −0.6, as the
thresholds of log2 ratio values for single copy number gains and losses,
and high-level number gains and homozygous deletions, respectively.
Using the rank segmentation algorithm, copy number was estimated
in each sample, with the signiﬁcance threshold set at p-value b 0.001.
We considered regions of gains and losses that are present in ≥50% of
the 13 samples as recurrent. We showed that CSFTCs exhibited a wide
array of alterations, including frequent gains in 1q and 8q and loss in
8p and 16q [1] (Fig. 3). These aberrations are also frequently found
in primary breast cancers [12,13].
CSFTC% PT%
FG
A%
Fig. 2. Fraction of genome altered (FGA) in cerebrospinal ﬂuid tumor cells (CSFTC) and
corresponding primary tumors (PT). The plot shows the medians for the fraction of ge-
nome lost and fraction of genome gained for 6 pairs of matched CSFTCs and PT. The sum
of the fraction of genome lost and gained is equal to the FGA.
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We describe, to our knowledge, the ﬁrst genome-wide ACGH data
on tumor cells isolated from the CSF (i.e., CSFTCs). We also provide, in
some patients, the ACGH data on corresponding primary and/or meta-
static tumors. We showed that the data are of high quality as indicated
by lowMADestimates. In addition, the genomic aberrationswe found in
CSFTCswere similar to those frequently observed in primary breast can-
cers. Furthermore, in the original paper [1], we demonstrated the clon-
al relationship of CSFTCs and their corresponding primary tumors.
Interestingly, we found more copy number alterations in CSFTCs as
compared to the latter, suggesting the acquisition of additional aberra-
tions in CSFTCs or that less normal DNA contamination was present in
our CSFTC samples. Finally, our genome-wide copy number analysis
was performed using BAC arrays with a 1.2 Mb resolution. Therefore,
further molecular studies on CSFTCs using oligoarrays and next genera-
tion sequencing are needed to facilitate further interrogation of the
CSFTC genome.Fig. 3. Copy number alterations in cerebrospinal ﬂuid tumor cells (CSFTCs). An ideogram show
diagnosed with leptomeningeal carcinomatosis. Chromosome regions with gains and losses
Nexus 6.1. The observed gain and loss of X- and Y-chromosomes, respectively, are a result of int
test versus male reference).Conﬂict of interest
J.W. Park has received commercial research grant support from
Veridex LLC. No potential conﬂicts of interest were disclosed by the
other authors.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gdata.2014.04.003.
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